Hormone receptor

Anixa Biosciences to Present at the Ovarian Cancer Research Alliance (OCRA) Ovarian Cancer National Conference

Retrieved on: 
Tuesday, October 31, 2023

SAN JOSE, Calif., Oct. 31, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it will present at the Ovarian Cancer National Conference taking place from November 1 – 3, 2023.

Key Points: 
  • "We are pleased to be presenting at the Ovarian Cancer National Conference," said Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences.
  • "We look forward to providing an overview of our Phase 1 ovarian cancer trial to an audience which is highly interested in new therapies to battle ovarian cancer."
  • The Ovarian Cancer National Conference is organized by the Ovarian Cancer Research Alliance ("OCRA").
  • The organization has invested $100 million in ovarian cancer research, educated 95,000 medical professionals, and advocated for $200 million in government research and education funding.

Anixa Biosciences Announces First Chinese Patent on its CAR-T Cancer Therapy Technology

Retrieved on: 
Wednesday, October 6, 2021

The patent is titled, "Methods and Compositions for Treating Cancer," and the inventors are Drs.

Key Points: 
  • The patent is titled, "Methods and Compositions for Treating Cancer," and the inventors are Drs.
  • Dr. Conejo-Garcia is Chair of the Department of Immunology at Moffitt Cancer Center and Dr. Perales-Puchalt is Vice President of R&D at Geneos Therapeutics.
  • The patent is assigned to The Wistar Institute and Anixa Biosciences' majority-owned subsidiary, Certainty Therapeutics, Inc. is the exclusive, world-wide licensee.
  • The therapy based on this technology was recently authorized by the U.S. Food and Drug Administration (FDA) for Phase 1 clinical testing.

Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Novel Oral Thyroid Receptor Beta Agonist VK0214

Retrieved on: 
Thursday, June 17, 2021

We look forward to evaluating VK0214 in X-ALD patients in our planned Phase 1b study and expect to have this trial underway shortly."

Key Points: 
  • We look forward to evaluating VK0214 in X-ALD patients in our planned Phase 1b study and expect to have this trial underway shortly."
  • Activation of the thyroid beta receptor has been shown to affect the expression of genes that are relevant to the manifestation of X-ALD.
  • In preclinical studies, VK0214 has been shown to potently activate the thyroid beta receptor, a regulator of ABCD2 gene expression, leading to increased expression of ABCD2.
  • The company is also developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD).

Global Polycystic Ovary Syndrome (PCOS) Market Study, 2015-2026: Key Marketed & Pipeline Drugs, Clinical Trials, Patent Information, 10-Year Disease Incidence Forecast, Licensing & Acquisition Deals - ResearchAndMarkets.com

Retrieved on: 
Monday, March 30, 2020

This Market Spotlight report covers the Polycystic Ovary Syndrome market, comprising key pipeline and marketed drugs, clinical trials, patent information, and a 10-year disease prevalence forecast, as well as licensing and acquisition deals.

Key Points: 
  • This Market Spotlight report covers the Polycystic Ovary Syndrome market, comprising key pipeline and marketed drugs, clinical trials, patent information, and a 10-year disease prevalence forecast, as well as licensing and acquisition deals.
  • The approved drugs in the PCOS space target estrogen receptor 1, androgen receptor, and follicle stimulating hormone receptor.
  • Therapies in the pipeline for PCOS focus on targets such as AMP-activated protein kinase, neurokinin receptor, and gonadotropin-releasing hormone receptor.
  • Merck KGaA leads industry sponsors with the highest overall number of clinical trials for PCOS, followed by AstraZeneca and Merck & Co.

World Endometriosis Markets, 2014-2019 & 2019-2026: Key Pipeline and Marketed Drugs, Clinical Trials, Upcoming and Regulatory Events, Patent Information, Licensing and Acquisition Deals

Retrieved on: 
Wednesday, June 19, 2019

Endometriosis affects an estimated one in 10 women in the reproductive age group of 15-49 years.

Key Points: 
  • Endometriosis affects an estimated one in 10 women in the reproductive age group of 15-49 years.
  • The approved drugs in the endometriosis space target the gonadotropin-releasing hormone receptor, progesterone receptor, follicle-stimulating hormone, and androgen receptors.
  • There have been 12 licensing and asset acquisition deals involving endometriosis drugs during 2014-19.
  • Bayer leads industry sponsors with the highest number of clinical trials for endometriosis, followed by Takeda.

World Endometriosis Market Spotlight 2019-2026 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 19, 2019

The "Market Spotlight: Endometriosis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Market Spotlight: Endometriosis" report has been added to ResearchAndMarkets.com's offering.
  • Endometriosis affects an estimated one in 10 women in the reproductive age group of 15-49 years.
  • The approved drugs in the endometriosis space target the gonadotropin-releasing hormone receptor, progesterone receptor, follicle-stimulating hormone, and androgen receptors.
  • Bayer leads industry sponsors with the highest number of clinical trials for endometriosis, followed by Takeda.

Viking Therapeutics to Participate in Upcoming Investor Conferences

Retrieved on: 
Tuesday, April 30, 2019

SAN DIEGO, April 30, 2019 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, todayannounced that the company will participate in two upcoming investor conferences.

Key Points: 
  • SAN DIEGO, April 30, 2019 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, todayannounced that the company will participate in two upcoming investor conferences.
  • Viking's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives.
  • The company's clinical programs include VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders, including non-alcoholic steatohepatitis (NASH).
  • The company is also developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of X-linked adrenoleukodystrophy (X-ALD).